Aeglea BioTherapeutics Inc Stock, NASDAQ:AGLE
805 Las Cimas Parkway, Suite 100, Austin, Texas 78746
United States of America
Number of Employees: 90
Aeglea Biotherapeutics, Inc. operates as a clinical-stage biotechnology company, which develops next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe in December 2013 and is headquartered in Austin, TX.